Wordt geladen...
Denosumab for the treatment of osteoporosis
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand patients being followed for up to 10 years. Combined w...
Bewaard in:
| Gepubliceerd in: | Osteoporos Sarcopenia |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Korean Society of Osteoporosis
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6372782/ https://ncbi.nlm.nih.gov/pubmed/30775498 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.afos.2017.01.002 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|